Reasons for Investigators to Participate Industry Sponsored Clinical Trials
![]() |
Kim, Joon-Hyung
(GlaxoSmithKline)
Choi, Won (GlaxoSmithKline) Beck, Sung-Ho (GlaxoSmithKline) Park, Soo-Jeong (GlaxoSmithKline) Park, Soo-Yeon (GlaxoSmithKline) Sohn, Woo-Yun (GlaxoSmithKline) Kim, Hyun-Ho (GlaxoSmithKline) Kim, Seung-Soo (GlaxoSmithKline) Lee, Han-Kyu (GlaxoSmithKline) Ahn, Jung-Ryun (GlaxoSmithKline) Kim, Yoon-Jung (GlaxoSmithKline) Seo, Jung-Min (Graduate School of Public Health, Yonsei University) Nam, Chung-Mo (Department of Preventire Medicine, Yonsei Univercity) Lee, Yil-Seob (GlaxoSmithKline) |
1 | Karlberg JP. Industry sponsored clinical trials in South Korea. Clinical Trial Magnifier, 2008;1(9):179-194. |
2 | Brandt S, Hartmann J, Hehner S. How to design a successful disease-management program. McKinsey Quarterly, 2010; https://www. mckinseyquarterly.com/How_to_design_a_ successful_disease-management_program_2685. Accessed 27 Dec, 2010. |
3 | Karlberg JP, Yau HK. Magnifier subscriber survey - incentives for participation in industry Sponsored Clinical Trials. Clinical Trial Magnifier, January 2009;2(1):37-51. |
4 | Lee SM, Bang JS, Kim YI, Kim KS, La HO. The present state and revitalization plan for clinical trials in the medical institutions: a comparison study to the year 2003. Kor J Clin Pharmacol The, 2008;16(2):101-110. |
5 | Rendell JM, Merritt RK, Geddes J. Incentives and disincentives to participation by clinicians in randomised controlled trials. Cochrane Database Syst Rev, 2007;18(2):1-25. |
![]() |